Aurobindo Pharma Limited — Others, 01-03-2025: Action(s) initiated or orders passed

Aurobindo Pharma has received an order demanding the reversal of Input Tax Credit (ITC) amounting to ₹4.60 crore (cr), including penalties and interest, for the fiscal year 2020-21. The company is accused of excess ITC claims relative to its GSTR filings. Despite this development, management indicates that the order won't materially impact financials or operations. Aurobindo plans to appeal the decision. Investors may perceive a neutral impact here, with potential risks related to litigation but no immediate adverse effects on the company's financial health.